{"schema_version":"secwatch.filing_event.v1","accession":"0000818479-23-000052","form_type":"8-K","ticker":"XRAY","cik":"0000818479","company_name":"DENTSPLY SIRONA Inc.","filed_at":"2023-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.722179+00:00","generated_at":"2026-06-12T15:43:18.290334+00:00","sec_items":["2.02","5.03","7.01","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Dentsply Sirona Q2 organic sales +2.3%, raises FY guidance; discloses material weakness","bullets":["Q2 net sales $1,028M (+0.5% reported, +2.3% organic); GAAP EPS $0.40, adj. EPS $0.51.","Raises FY23 net sales midpoint by $75M to $3.98-4.02B; adj. EPS outlook to $1.92-2.02.","Discloses new material weakness over manual journal entry segregation of duties as of Dec. 31, 2022.","Prior 10-K and Q1 10-Q internal control reports no longer reliable; financial statements unchanged.","Effective Q2 2023, reportable segments realigned to four: Connected Tech, Essential Dental, Ortho/Implant, Wellspect."],"urls":{"canonical":"https://secwatch.observer/filing/0000818479-23-000052","json":"https://secwatch.observer/filing/0000818479-23-000052.json","markdown":"https://secwatch.observer/filing/0000818479-23-000052.md","text":"https://secwatch.observer/filing/0000818479-23-000052.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818479/000081847923000052/0000818479-23-000052-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818479/000081847923000052/xray-20230802.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T15:43:18.290334+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"969dc5135ec2ea705ff94519db97e70f6e8e35ef","claim":"DENTSPLY SIRONA Inc. reported second quarter ended June 30, 2023 results: revenue $1,028 million, net income $86 million, EPS $0.40 per diluted share. Guidance raised.","evidence_excerpt":"Second quarter net sales of $1,028 million increased 0.5% (organic sales increased 2.3%), compared to $1,023 million in the second quarter of 2022. Net income for the second quarter of 2023 was $86 million, or $0.40 per diluted share, compared to net income of $73 million, or $0.34 per diluted share in the second quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/818479/000081847923000052/0000818479-23-000052-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Revenue","value":"$1,028 million"},{"label":"Net income","value":"$86 million"},{"label":"EPS","value":"$0.40 per diluted share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"a25230d6850d2fe85c1d30fe0de6e9865c828bc1","claim":"DENTSPLY SIRONA Inc.: Amended and Restated By-laws to adopt Universal Proxy Rule requirements and conform to recent Delaware law amendments, effective immediately (effective 2023-07-27).","evidence_excerpt":"On July 27, 2023, the Board of Directors (the “Board”) of DENTSPLY SIRONA Inc. (the “Company”) adopted and approved the Seventh Amended and Restated By-laws of the Company (as amended and restated, the “Amended and Restated Bylaws”), effective immediately.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/818479/000081847923000052/0000818479-23-000052-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-07-27"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}